Novavax Showcases Data from Expanding Vaccine Portfolio at IDWeek 2022
prnewswire.com
news
2022-10-20 18:15:00

New Phase 3 PREVENT-19 data reinforce the Novavax COVID-19 vaccine's benefits as an adult booster in both younger and older adults, and with varying time intervals for the booster dose 
Phase 1/2 trial data show COVID-19-Influenza Combination vaccine candidate induced antibody and T-cell responses against SARS-CoV-2 and homologous and heterologous influenza strains 

GAITHERSBURG, Md., Oct. 20, 2022 /PRNewswire/ --Â Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, will present new data from the Phase 3 PREVENT-19 trial evaluating its protein-based COVID-19 vaccine (NVX-CoV2373) as a booster in adults, including a breakdown by age and by booster dose interval (8 and 11 months) at IDWeek 2022, October 20 to 22, 2022.
